BTIG Reiterates Buy on Starling Oncology, Maintains $10 Price Target
Lake Street Maintains Buy on Starling Oncology, Lowers Price Target to $8
Oncology Institute Q3 Earnings Call Highlights
B. Riley Securities Reiterates Buy on Starling Oncology, Lowers Price Target to $10
Starling Oncology, Inc. (STLN) Q3 2026 Earnings Call Transcript
BTIG Maintains Buy on Starling Oncology, Raises Price Target to $10
Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
Starling Oncology Q3 2026 Earnings Call Transcript
Starling Oncology Narrows FY2026 Sales Guidance from $650.000M-$670.000M to $650.000M-$660.000M vs $663.685M Est
Starling Oncology Q3 EPS $(0.13) Misses $(0.05) Estimate, Sales $169.767M Beat $169.047M Estimate
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
Starling Oncology (STLN) Stock Gets Fair Value Boost On Capitated Revenue And Nexus Views
Needham Maintains Buy on Starling Oncology, Raises Price Target to $9
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Starling Oncology: Improving Cash Flow And Gross Profit Fuel A Re-Rating
Starling Oncology to Participate in Wells Fargo Healthcare Conference
Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
Oncology Institute Q2 Earnings Call Highlights
Starling Oncology shares are trading higher after the company reported a year-over-year decrease in Q2 loss per share and increase in sales results.
Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.